Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Foghorn Announced That Eli Lilly Has Selected FHD-909 For Clinical Development. Lilly Plans To File An Investigational New Drug Application In Q2 2024, Primary Target Patient Population Is BRG1 Mutated Non-small Cell Lung Cancer

Author: Benzinga Newsdesk | February 08, 2024 08:13am

. The primary target patient population is BRG1 mutated non-small cell lung cancer (NSCLC).

Posted In: FHTX LLY